Drug Profile


Alternative Names: INGREZZA; MT 5199; NBI-98854; Valbenazine-tosylate; VMAT2-inhibtor-Neurocrine-Biosciences

Latest Information Update: 09 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Neurocrine Biosciences
  • Developer Mitsubishi Tanabe Pharma Corporation; Neurocrine Biosciences
  • Class 3-ring heterocyclic compounds; Amino acids; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Drug-induced dyskinesia
  • Phase II Gilles de la Tourette's syndrome
  • Discontinued Huntington's disease; Schizophrenia

Most Recent Events

  • 03 Aug 2017 Neurocrine Biosciences files sNDA for valbenazine 80mg capsules for treatment of patients with Drug-induced dyskinesia in USA
  • 03 Aug 2017 US FDA assigns PDUFA action date of 14/10/2017 for valbenazine 80mg capsules for Drug-induced dyskinesia
  • 03 Aug 2017 Primary endpoint not met in the phase II T-Force GREEN trial in Gilles de la Tourette's syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top